Neoadj Tx pt w/ ER-neg/HER2+ T3 LABC wanting breast conservation?
Which neoadjuvant treatment do you generally use for a patient with locally advanced (T3 lesion), ER-negative, HER2-positive breast cancer who desires breast conservation?
APHINITY trial: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. NCT01358877
Buzdar, A et al. ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Proc ASCO 2013;Abstract 502.
Gianni L et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32. Abstract
I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular analysis 2). NCT01042379
Schneeweiss A et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with anthracycline-containing or concurrent with anthracycline-free standard regimen: A randomized phase II study (TRYPHAENA). San Antonio Breast Cancer Symposium 2011;Abstract S5-6.